A 32-year-old woman with multiple sclerosis (MS) presents to her GP with a five-day history of numbness and weakness in the right leg. She feels well in herself and does not describe any symptoms to suggest an intercurrent infection. She has been taking weekly intramuscular injections of interferon-β1a for the last 18 months and reports flu-like symptoms that can last for up to 24 hours after each dose. She asks if there is a need to change her treatment and what alternatives are available.
Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disorder of the central nervous system affecting over 2 million people worldwide. [1] It is a major cause of physical disability in young adults and has profound implications for cognition, emotional well-being and employment. Patients commonly present with unilateral visual loss (due to optic neuritis), double vision, sensory symptoms, limb weakness or imbalance. [2] The diagnosis is based on clinical features and MRI findings, sometimes supported by lumbar puncture and other investigations. [2, 3] Nearly 80-85% of people with MS experience a relapsing course with episodes of new or worsening neurological symptoms lasting at least 24 hours followed by full or partial recovery, in the absence of fever or infection (attacks or relapses). [3] Untreated, most people with relapsing MS develop disability over time due to incomplete recovery from relapses, or a change in disease course to progressive MS, with a steady increase in disability. In 10-15% of people with MS, the disease is progressive from onset (primary progressive MS [ 
PPMS]). [Box 1]

What treatments are available for MS?
Currently, 15 disease-modifying therapies (DMTs) are licenced for relapsing MS, including five preparations of interferon-β and three preparations of glatiramer acetate [2, 4] . A number of oral and monoclonal antibody therapies for MS have become available in the last decade ( Figure 1 ). Ocrelizumab [5] International guidelines on starting, switching and stopping DMTs in people with MS (Box 2) recommend offering DMTs to patients with active relapsing MS. [6] [7] [8] No treatment is advised for patients with inactive MS [8] . The ECTRIMS/EAN and AAN guidelines recommend offering interferon-β or glatiramer acetate in patients with a clinically isolated syndrome, i.e. the first episode of neurological symptoms suggestive of MS with brain MRI abnormalities (indicating a high-risk of MS), to delay the second attack, and ocrelizumab in patients with PPMS. [6, 7] How well do they work?
There is moderate to high quality evidence from phase III randomised controlled trials and systematic reviews [9, 10] that DMTs reduce the relative risk of developing relapses (Table 1) , accumulation of new brain MRI lesions, and disability progression over 2-3 years in active relapsing MS, compared with placebo, or an active comparator (interferon-β). [4] The use of relative measures over absolute measures is preferred to compare the efficacy of two treatments in MS because the former appear to be more stable across populations of patients with different relapse and MRI measures of disease activity. [11, 12] When recommending starting a DMT, a clinician might discuss with the patient that being on that medication -rather than being on no medications at all -will reduce the risk of developing relapses by a certain percentage as found in large clinical trials (Table 1) . DMTs generally do not improve established symptoms of MS, although a pivotal trial [13] showed that alemtuzumab treated patients were more than twice as likely as interferon-β treated patients to experience 6-month confirmed disability improvement (28.8% vs 12.9%, Hazard Ratio [HR]= 2.57, p=0.0002), and a post-hoc study from another pivotal trial showed that natalizumab [14] licenced drugs for relapsing MS, alemtuzumab, natalizumab, and ocrelizumab had the greatest reduction in the annualised relapse rates (approximately 70% reduction compared to placebo), fingolimod, and dimethyl fumarate were the next most effective (47% to 54% reduction) and the interferons, glatiramer acetate and teriflunomide were less effective (17% to 37% reduction). This analysis is limited by the short-term follow-ups of the included studies and the lack of head-to-head trials.
Furthermore, it pointed out that the evolving MS diagnostic criteria over the past 2 decades have caused important variation among the studied patient populations across trials.
What are the harms?
Very common (≥10% of patients) or common (≥1% to <10% of patients) adverse reactions of DMTs, as reported in the relevant summaries of product characteristics, include: flu-like symptoms (interferon-β); headache (interferon-β, fingolimod); gastrointestinal upset (dimethyl fumarate, teriflunomide); injection site reactions (interferon-β, glatiramer acetate). These are generally mild but can impact on adherence, and sometimes require a change of treatment. Infusion reactions occur commonly with alemtuzumab and ocrelizumab.
Interferon-β and glatiramer acetate have an excellent long-term safety profile, as shown by long-term observational studies. [20] [21] [22] The oral and monoclonal antibody treatments for MS can have serious adverse reactions including opportunistic infections, cardiac arrhythmias, hepatotoxicity and secondary autoimmunity (Table   1) , and the long-term safety profile of these DMTs is unknown. Daclizumab, an anti-CD25 monoclonal antibody, has recently been withdrawn following cases of severe liver injury and immune-mediated encephalitis not observed in phase III clinical trials.
Post-authorisation safety studies and pharmacovigilance are essential for all newly approved DMTs, and can lead to marketing authorisation changes by the regulatory agencies. DMTs may be associated with serious adverse reactions (see below).
Natalizumab and alemtuzumab are subject to a Risk Evaluation and Mitigation Strategy (REMS) by the FDA, requiring training and support for healthcare providers to monitor patients during treatment to reduce the occurrence and/or severity of serious risks.
Progressive multifocal leukoencephalopathy
Progressive multifocal leukoencephalopathy (PML), due to reactivation of the John Cunningham virus (JCV), is an opportunistic brain infection that can complicate treatment with natalizumab and is associated with high rates of death or disability.
JCV serostatus and antibody index should be checked before starting natalizumab (and periodically during treatment) to stratify PML risk. PML has rarely been reported in patients with fingolimod (estimated risk <1:10,000) and dimethyl fumarate who have not been treated with natalizumab.
Cardiac arrhythmias
Fingolimod causes first-dose bradycardia (~1-2%), and rarely transient heart block (<0.5%). An electrocardiogram should be obtained prior to starting treatment and the first dose administered with heart rate monitoring for 6 hours after the first dose.
Cases of ventricular tachycardia and sudden cardiac death have also been reported with fingolimod. Fingolimod should be avoided in patients with a history of ischemic heart disease or cardiac arrhythmias.
Hepatotoxicity
Deranged liver function tests (LFTs) commonly occur with a number of DMTs (particularly interferon-β, dimethyl fumarate, fingolimod). Individual cases of fatal liver injury have been reported with leflunomide (the pro-drug of teriflunomide).
Teriflunomide should be avoided in people with a history of liver disease.
Secondary autoimmunity
Autoimmune thyroid disease, immune thrombocytopenic purpura and glomerulonephritis may occur in people treated with alemtuzumab, most often in the second or third year after starting treatment (risk of secondary autoimmunity ~50% at 5 years).
Malignancy
DMTs should not be prescribed in patients with an active malignancy, and the safety in patients with a history of cancer is uncertain. Fingolimod is associated with an increased risk of skin cancers, particularly basal cell carcinoma. Mitoxantrone is associated with an increased risk of acute myeloid leukaemia (0.5-1%), and possibly solid-organ cancers. The long-term risk of cancer with other DMTs is unknown.
How are they given and monitored?
DMTs are prescribed and monitored in secondary care, often through specialist MS clinics with neurologists, nurse specialists and pharmacists. The route Periodic clinical reviews to check for relapses and/or disability progression plus MRI scanning are used to monitor response to treatment. Evidence of disease activity on MRI is associated with an increased risk of disability progression, even in patients who are stable clinically [23, 24] . Some neurologists use the target of "no evidence of disease activity" (NEDA) when treating relapsing MS, recommending a change of treatment if there are ongoing relapses, new MRI activity or disability progression [25] . There is conflicting evidence on the benefits of this approach [26, 27] .
How cost-effective are they?
DMTs account for over half of direct medical costs in people with MS. [28] There is wide variation in the cost of DMTs between countries. The cost of DMTs has increased dramatically in the United States over the last 10 years with 10-15% increase annually. The annual cost of most DMTs now exceeds US$70,000/year.
[28] A number of studies have found that DMTs are not cost-effective at accepted economic thresholds. [28] A recent analysis from the Institute of Clinical and Economic Review found that among the currently available DMTs, alemtuzumab may be most cost-effective because of the combination high-efficacy and unique dosing strategy (two cycles of treatment over 2 years with further treatment given only if needed). [10] Lower drug pricing (as in the United Kingdom [29] ), the availability of generics [30] , off-label prescribing (e.g. rituximab [31] ), and the increasing use of DMTs that do not require ongoing maintenance treatment may improve cost-effectiveness.
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What you need to know
Education into practice
 Are all your patients with active relapsing MS referred to a neurologist for a discussion regarding DMTs?
 Are women you see who take DMTs using effective contraception?
 Consider placing an alert on the electronic patient record for people receiving DMTs so that complications of treatment are recognised promptly in patients presenting acutely in primary or secondary care.
How patients were involved in the creation of this article
We asked two patients who attend our specialist MS clinic to comment on the draft manuscript and develop the Tips for Patients section. They highlighted the importance of early referral to a specialist MS team, the importance of lifestyle factors and burden of monitoring when selecting DMTs, and contraception/preconception counselling in women with MS.
FIGURE AND BOX LEGEND
Figure 1. Timeline of the approved disease-modifying therapies
The figure shows the timeline of the approved DMTs for relapsing MS according by the FDA (on the top) and the EMA (on the bottom).
DMT= disease-modifying therapy; EMA= European Medicines Agency; FDA= Food and Drug Administration; MS= multiple sclerosis.
± Daclizumab (Zynbrita®, Biogen) has been withdrawn from the market by Biogen in March 2018, due to cases of encephalitis and meningoencephalitis. § Glatiramer acetate was approved after Mutual Recognition Procedure in Europe (the UK was the reference member state) and not formally by the EMA. Glatiramer acetate (Copaxone®, Teva) was approved in the UK in 2000.
# Mitoxantrone has been authorised in the EU via national procedures and not initially formally reviewed by the EMA. In 2016, the EMA was asked to harmonise the marketing authorisations in the EU. The EMA declared that Mitoxantrone is indicated for treatment of patients with highly active relapsing MS associated with rapidly evolving disability where no alternative therapeutic options exist. 
An approach to treating multiple sclerosis
The box shows an approach to treat relapsing MS according to the EMA, with a mention to the FDA indications. The EMA allows the prescription of some treatments (natalizumab, fingolimod, cladribine, mitoxantrone) to patients with highly-active MS. Of note, the FDA does not group patients according to disease activity (i.e. active or highly active) but rather on patients' response to DMTs (i.e. if patients develop relapses or new/enlarged or gadolinium enhancing lesions while on DMTs). Figure 1 28 Figure 2 
